ArticleThe Indian journal of medical research2025
Body composition following gender affirming hormone therapy in transgender individuals.
Article in The Indian journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & objectivesGender-affirming hormone therapy may alter body composition and muscle strength, which may impact participation in sports and other activities. These changes are important to decide whether transgender should have separate categories of competition. MethodsWe conducted this prospective study, to assess the body composition using bioelectrical impedance analysis muscle strength and serum irisin levels at baseline and at 12 months following gender affirming hormone therapy in transgender individuals. The comparisons were done in both cis mode and trans mode. ResultsA total of 32 transfemales and 22 transmales were included in the study. Among transwomen, there was an increase in total subcutaneous fat (9.2%) and visceral fat (11.3 %) (P<0.001 in both cis and trans mode comparison) and a decrease in muscle mass (7.7%) (P=0.033 and P<0.001 in cis and trans mode, respectively) and muscle strength at all sites (P<0.001). Among transmen, there was a decrease in total subcutaneous fat (5.9%) (P<0.001 for both cis and trans mode comparison) and an increase in muscle mass (7.2 %) (P<0.001 for trans mode only) and muscle strength except shoulder abduction on right side (P<0.001). No significant changes were observed in irisin levels following hormonal therapy. Interpretation & conclusionsGender affirming hormonal therapy leads to body fat redistribution after twelve months of hormone therapy with significant alterations in muscle mass and strength among both transmen and transwomen. Irisin, an adipomyokine produced through muscle contraction, did not correlate with muscle mass or fat mass on follow up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.